Imperial College London

Matt Fuchter wins Tetrahedron Young Investigator Award

by

Dr Matthew Fuchter

Dr Matthew Fuchter

Dr Matthew Fuchter, who works on synthesis of new drugs for diseases, has won one of the journal Tetrahedron's flagship prizes.

The Tetrahedron Young Investigator Awards were created in 2005 by the Executive Board of Editors and the Publisher of Tetrahedron Publications. There are two new awards, which are annually presented to two individuals who have exhibited "exceptional creativity and dedication" in the fields of Organic Synthesis and of Bioorganic and Medicinal Chemistry.

I hope we can continue to build on our early successes, and, ultimately, contribute to improved treatments for a range of diseases.

– Dr Matthew Fuchter

Dr Fuchter has won the award for Bioorganic and Medicinal Chemistry. He will receive a certificate and an award of US $3,000, as well as having a Symposium-in-Print compiled in his honour.

Along with his co-winner, Dr Seth Herzon from Yale University, Dr Fuchter will give a plenary lecture at the 19th Tetrahedron Symposium, where he will be formally presented with his award.

Dr Fuchter is a Reader in Synthetic and Medicinal Chemistry, the Director of Postgraduate Studies, and a co-Director of the MRes in Drug Discovery in the Department of Chemistry at Imperial College London.

He is involved in multiple multidisciplinary centres of excellence at Imperial, including the Institute of Chemical Biology, the Imperial College Network of Excellence in Malaria, the Antimicrobial Research Collaborative, and the Imperial College Cancer Research UK Centre.

The Fuchter group has a wide-ranging track record in the design, synthesis and application of organic molecules in chemistry, medicine and materials. On winning the award, Dr Fuchter said: "I feel immensely proud and honoured to have been selected as a recipient of the Tetrahedron Young Investigator Award.

“I would like to thank my research group and my collaborators for all their efforts that led to this recognition. I hope we can continue to build on our early successes, and, ultimately, contribute to improved treatments for a range of diseases.”

Reporter

Hayley Dunning

Hayley Dunning
Communications and Public Affairs

Click to expand or contract

Contact details

Tel: +44 (0)20 7594 2412
Email: h.dunning@imperial.ac.uk

Show all stories by this author